Companies › Neogap Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| pTTL (personal tumour-trained lymphocytes) Autologous cell product: patient-derived tumor-draining lymph node T cells expanded in vit | – | Phase 1 | Colorectal Cancer | Dec 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05908643 | pTTL (personal tumour-trained lymphocytes) | Phase 1 | Colorectal Cancer | Oncology | Dec 2030 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.